AT least 4,800 people living with HIV/Aids in Gulu district have received food supplements from the World Food Programme (WFP) and the World Vision.
Kimera Mutebi, The AIDS Support Organisation (TASO) district manager, recently said 7,920 people had registered for the programme.
He added that 2,500 people will receive nutritional supplements supplied by ACDI/VOCA, a USAID-funded organisation
read more
Monday, September 17, 2007
Nigeria: NGO Declares Nov 29 N-Delta Aids/HIV Day
IN the fight to eradicate the pandemic HIV/AIDS scourge and educate/enlighten the suffering masses in the Niger Delta region, a non-governmental organization, Niger-Delta HIV/AIDS Prevention Initiative has declared the 29th of November, 2007 as Niger-Delta HIV/AIDS Day just as the region is alleged to harbour more than 60% of HIV/AIDS patients in the country.
He stated that a year long research by the organization reveals a gory picture of the spread and prevalence of the aids scourge against the claims of the National Agency for Control of HIV/AIDS that 90% of Nigerians are now aware of the deadly disease. read more
He stated that a year long research by the organization reveals a gory picture of the spread and prevalence of the aids scourge against the claims of the National Agency for Control of HIV/AIDS that 90% of Nigerians are now aware of the deadly disease. read more
New study on HIV/AIDS
Researchers, at Vanderbilt University Medical Center, reported that HIV infected women, who become pregnant have a lower risk of progression to AIDS and death. Their findings suggested that “the complex set of immunologic changes” that occur during pregnancy may be interacting as a benefactor with the combination drug therapy.
“After using statistical modelling methods to adjust for differences between women, including their age, health and response to therapy, the researchers found that ‘pregnant women did better’ read more
“After using statistical modelling methods to adjust for differences between women, including their age, health and response to therapy, the researchers found that ‘pregnant women did better’ read more
UPDATE 1-Schering-Plough HIV drug begins late-stage trials
Schering-Plough Corp. (SGP.N: Quote, Profile, Research) said on Monday that it had begun late-stage trials of an experimental HIV drug that showed promising effectiveness in earlier studies but aroused safety concerns because of cancers seen in some patients taking it.
The U.S. drugmaker said it had begun two Phase III trials of vicriviroc, a once-daily tablet that works through the same mechanism as Pfizer Inc's (PFE.N: Quote, Profile, Research) recently approved Selzentry, or maraviroc. Both potentially can help patients whose virus has become resistant to earlier HIV treatments.
read more
The U.S. drugmaker said it had begun two Phase III trials of vicriviroc, a once-daily tablet that works through the same mechanism as Pfizer Inc's (PFE.N: Quote, Profile, Research) recently approved Selzentry, or maraviroc. Both potentially can help patients whose virus has become resistant to earlier HIV treatments.
read more
Botswana: HIV Threatens Child Survival
Paediatric HIV care is still a major challenge in southern Africa and only a small number of affected children have access to treatment, a senior health official says.
Officially closing the first regional training workshop on paediatric HIV care at Baylor's Children's Clinical Centre of Excellence in Gaborone, Barbara Mudanga, chief health officer at the Ministry of Health, department of HIV/AIDS prevention and care, said that child survival in the region has been seriously affected by the HIV/AIDS epidemic.
She noted that in Botswana, 10 percent of the people on treatment are children under the age of 15. read more
Officially closing the first regional training workshop on paediatric HIV care at Baylor's Children's Clinical Centre of Excellence in Gaborone, Barbara Mudanga, chief health officer at the Ministry of Health, department of HIV/AIDS prevention and care, said that child survival in the region has been seriously affected by the HIV/AIDS epidemic.
She noted that in Botswana, 10 percent of the people on treatment are children under the age of 15. read more
East Africa: Mainstream HIV/Aids Into Regional Agenda
The East African Community (EAC) leaders should include checking the spread and devastating effects of HIV/AIDS in the community's agenda.
If this is not done, says Dr Calleb Weggoro, the EAC director for the productive and social sector, business in the East African region could be in jeopardy.
Speaking at a workshop of medical and gender practitioners from EAC member states last week, Weggoro said that despite the fact that individual countries allocate funds for AIDS activities in their national budgets, an EAC arrangement should be put in place to accelerate efforts against the spread of the disease
read more
If this is not done, says Dr Calleb Weggoro, the EAC director for the productive and social sector, business in the East African region could be in jeopardy.
Speaking at a workshop of medical and gender practitioners from EAC member states last week, Weggoro said that despite the fact that individual countries allocate funds for AIDS activities in their national budgets, an EAC arrangement should be put in place to accelerate efforts against the spread of the disease
read more
SRI helps develop high-speed screening process
A North Carolina company, in collaboration with Birmingham's Southern Research Institute, has developed a high-speed screening process to identify new compounds for treating the virus that causes AIDS.
Trana Discovery, based in Cary, N.C., said its new process will allow pharmaceutical companies to screen "vast libraries of compounds" to identify those that interrupt the lifecycle of HIV. Trana said the technology has the potential to discover new classes of medicines for the treatment of HIV that may overcome resistance mechanisms associated with current therapies.
read more
Trana Discovery, based in Cary, N.C., said its new process will allow pharmaceutical companies to screen "vast libraries of compounds" to identify those that interrupt the lifecycle of HIV. Trana said the technology has the potential to discover new classes of medicines for the treatment of HIV that may overcome resistance mechanisms associated with current therapies.
read more
Subscribe to:
Posts (Atom)
